ERBB2 and cancer: We suggested the importance of exploiting features coming from different imaging modalities, as also reported in Liu et al. [56], where they use conventional T2, DWI, and T1w DCE imaging to predict cancer subgroups and in particular to distinguish between HER2-positive/negative receptor status.